Clinical trials: active, in Mauritius
Rheumatoid Arthritis
Study of PTC844 in Participants With Active Rheumatoid Arthritis
This study is designed to assess the safety, pharmacokinetics (PK), and biomarker effects of PTC844 compared to placebo in participants with active rheumatoid arthritis (RA).
- Trial name
- NCT07779616
- Testing
- PTC844
- Where
- 26 sites in United States, Georgia and 2 more
- Volunteers
- 75 people
- Sponsor
- PTC Therapeutics
Advanced Solid Tumor
Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access Program
Envafolimab is a novel PD-L1 inhibitor administered via subcutaneous (SC) injection - notably the first such checkpoint inhibitor approved for use worldwide.[1] In November 2021, Envafolimab received its first approval in China…
- Trial name
- ENCOMPASS STUD (NCT07562347)
- Testing
- Envafolimab
- Where
- 4 sites in Kenya, Mauritius and 1 more
- Volunteers
- 120 people
- Sponsor
- IR INNOVATE RESEARCH PRIVATE LIMITED
Undiagnosed Diseases, Rare Diseases
Genetic Analysis of Uncommon Disease Presentations in Non-US Populations
Background: Genetics research over the past 20 years has helped researchers find the causes of many diseases. More powerful tools for genetic testing now exist.
- Trial name
- NCT06595940
- Where
- Mauritius
- Volunteers
- 400 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Systemic Lupus Erythematosus
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus…
- Trial name
- NCT05540327
- Testing
- M5049 low dose, M5049 medium dose, M5049 high dose
- Where
- 122 sites in United States, Argentina and 20 more
- Volunteers
- 381 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Bacterial Vaginosis, Vaginal Candidiasis
Multi-Gyn FemiTotal for the Treatment and Prevention of Vulvovaginal Candidiasis Symptoms and Bacterial Vaginosis
The goal of this clinical trial is to assess the safety and efficacy of Multi-Gyn Femitotal to treat and prevent women suffering from bacterial vaginosis and vulvo vaginal candidiasis.
- Trial name
- NCT07234786
- Testing
- Multi-Gyn FemiTotal
- Where
- Mauritius
- Volunteers
- 80 people
- Sponsor
- Karo Pharma AB
Systemic Lupus Erythematosus
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18…
- Trial name
- APATURA (NCT05039840)
- Testing
- SAR441344 IV, SAR441344 SC
- Where
- 73 sites in United States, Argentina and 14 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Atherosclerotic Cardiovascular Disease
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
- Trial name
- VICTORION-2P (NCT05030428)
- Testing
- Inclisiran sodium 300 mg
- Where
- 983 sites in United States, Argentina and 48 more
- Volunteers
- 17,004 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks
Pierre Fabre Laboratories have developed a cream with medical device status, RV4421B-EV0407 indicated for the treatment of eczemas, including atopic eczema, contact eczema and chronic hand eczema.
- Trial name
- NCT07014007
- Testing
- RV4421B- EV0407
- Where
- Mauritius
- Volunteers
- 105 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Headlice
Comparative Study for the Evaluation of a New Medical Device Shampoo on the Treatment of Head Lice Infestation
Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice).
- Trial name
- NCT07391059
- Testing
- COMPARATOR DEVICE, Pouxit ®
- Where
- Mauritius
- Volunteers
- 180 people
- Sponsor
- Perrigo CSCI
Solar Lentigo
CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS
To assess the efficacy of the Epilady investigational device, used with and without a topical depigmenting formula, in reducing the appearance of lentigo spots on the hands and forearms of healthy female participants over an…
- Trial name
- EPILADY (NCT07239726)
- Testing
- LASER, LASER AND ACTIVE FORMULA
- Where
- Mauritius
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Healthy, Melasma (Facial Melasma)
COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS
The goal of this clinical trial is to compare the dermatological tolerance and skin-lightening efficacy of a cosmetic depigmenting serum to a 4% hydroquinone-based product in adult male and female subjects aged 18-65 years with…
- Conditions
- Healthy, Melasma (Facial Melasma), Epidermal Melasma
- Trial name
- NCT07071363
- Testing
- Depigmenting Cosmetic Serum (Applied Morning and Evening)
- Where
- Mauritius
- Volunteers
- 40 people
- Sponsor
- Laboratoire Dermatologique ACM
Diabete Mellitus, Cardiovascular Disease Risk Factor
The Mauritius and Rodrigues Non-Communicable Disease (NCD) Study
Mauritius is located in the southern Indian Ocean with a population of 1.3 million in 2023. Mauritius is a multiethnic nation with 68% South Asian, 27% African (Creole), 3% Chinese and 2% Franco Mauritians.
- Conditions
- Diabete Mellitus, Cardiovascular Disease Risk Factor, Ischemic Cardiovascular Disease, Hypertension
- Trial name
- NCT07048717
- Where
- Mauritius
- Volunteers
- 39,082 people, healthy volunteers welcome
- Sponsor
- Umeå University